|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2010-8-6
|
|
pubmed:abstractText |
Cyclophosphamide-based adjuvant chemotherapy is a mainstay of treatment for women with node-positive breast cancer, but is not universally effective in preventing recurrence. Pharmacogenetic variability in drug metabolism is one possible mechanism of treatment failure. We hypothesize that functional single nucleotide polymorphisms (SNPs) in drug metabolizing enzymes (DMEs) that activate (CYPs) or metabolize (GSTs) cyclophosphamide account for some of the observed variability in disease outcomes.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/20459744-10868689,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20459744-11036954,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20459744-11059750,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20459744-11470993,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20459744-11488937,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20459744-11585745,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20459744-12433731,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20459744-12840088,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20459744-12846892,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20459744-14673875,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20459744-16087946,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20459744-16409140,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20459744-18065748,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20459744-18496131,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20459744-18509327,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20459744-3290910,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20459744-3543359
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1465-542X
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
12
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
R26
|
|
pubmed:dateRevised |
2011-8-1
|
|
pubmed:meshHeading |
pubmed-meshheading:20459744-Adult,
pubmed-meshheading:20459744-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20459744-Breast Neoplasms,
pubmed-meshheading:20459744-Chemotherapy, Adjuvant,
pubmed-meshheading:20459744-Cohort Studies,
pubmed-meshheading:20459744-Cyclophosphamide,
pubmed-meshheading:20459744-Cytochrome P-450 CYP3A,
pubmed-meshheading:20459744-Doxorubicin,
pubmed-meshheading:20459744-Female,
pubmed-meshheading:20459744-Fluorouracil,
pubmed-meshheading:20459744-Humans,
pubmed-meshheading:20459744-Lymph Nodes,
pubmed-meshheading:20459744-Lymphatic Metastasis,
pubmed-meshheading:20459744-Middle Aged,
pubmed-meshheading:20459744-Polymorphism, Single Nucleotide,
pubmed-meshheading:20459744-Retrospective Studies,
pubmed-meshheading:20459744-Survival Rate,
pubmed-meshheading:20459744-Thiotepa,
pubmed-meshheading:20459744-Treatment Outcome,
pubmed-meshheading:20459744-Tumor Markers, Biological
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study.
|
|
pubmed:affiliation |
Center for Cancer and Hematologic Disease, 1930 E. Route 70, Cherry Hill, NJ 08003, USA. priyagor@hotmail.com
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Research Support, N.I.H., Extramural
|
